HC Wainwright Raises X4 Pharmaceuticals (NASDAQ:XFOR) Price Target to $5.00

X4 Pharmaceuticals (NASDAQ:XFOR) had its target price lifted by equities researchers at HC Wainwright from $3.00 to $5.00 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective points to a potential upside of 358.72% from the stock’s current price.

X4 Pharmaceuticals Stock Down 6.4 %

Shares of NASDAQ XFOR opened at $1.09 on Tuesday. X4 Pharmaceuticals has a 12-month low of $0.57 and a 12-month high of $2.58. The company has a market capitalization of $183.05 million, a PE ratio of -1.82 and a beta of 0.48. The company has a debt-to-equity ratio of 1.07, a current ratio of 5.34 and a quick ratio of 5.34. The firm’s 50-day moving average is $1.15 and its two-hundred day moving average is $0.93.

X4 Pharmaceuticals (NASDAQ:XFOR) last announced its quarterly earnings results on Thursday, March 21st. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.05. Equities analysts anticipate that X4 Pharmaceuticals will post -0.47 EPS for the current fiscal year.

Insider Activity at X4 Pharmaceuticals

In related news, CEO Paula Ragan sold 49,678 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $0.88, for a total transaction of $43,716.64. Following the transaction, the chief executive officer now owns 765,068 shares of the company’s stock, valued at $673,259.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, CEO Paula Ragan sold 49,678 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $0.88, for a total transaction of $43,716.64. Following the transaction, the chief executive officer now owns 765,068 shares of the company’s stock, valued at $673,259.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Adam S. Mostafa sold 27,721 shares of the company’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $1.01, for a total transaction of $27,998.21. Following the transaction, the chief financial officer now directly owns 52,500 shares in the company, valued at approximately $53,025. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 185,708 shares of company stock valued at $170,428. Company insiders own 1.08% of the company’s stock.

Hedge Funds Weigh In On X4 Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Kingdon Capital Management L.L.C. raised its stake in shares of X4 Pharmaceuticals by 76.0% in the 4th quarter. Kingdon Capital Management L.L.C. now owns 3,473,683 shares of the company’s stock valued at $2,913,000 after acquiring an additional 1,500,000 shares during the period. Bain Capital Life Sciences Investors LLC raised its stake in shares of X4 Pharmaceuticals by 6.0% in the 4th quarter. Bain Capital Life Sciences Investors LLC now owns 16,915,784 shares of the company’s stock valued at $14,184,000 after acquiring an additional 955,196 shares during the period. Stonepine Capital Management LLC raised its stake in shares of X4 Pharmaceuticals by 14.5% in the 3rd quarter. Stonepine Capital Management LLC now owns 5,273,685 shares of the company’s stock valued at $5,748,000 after acquiring an additional 668,422 shares during the period. GSA Capital Partners LLP purchased a new position in shares of X4 Pharmaceuticals in the 3rd quarter valued at $678,000. Finally, Barclays PLC raised its stake in shares of X4 Pharmaceuticals by 334.8% in the 3rd quarter. Barclays PLC now owns 382,134 shares of the company’s stock valued at $417,000 after acquiring an additional 294,255 shares during the period. Institutional investors and hedge funds own 72.03% of the company’s stock.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.